Literature DB >> 4344316

Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro.

D J Moss, J H Pope.   

Abstract

Entities:  

Mesh:

Year:  1972        PMID: 4344316     DOI: 10.1099/0022-1317-17-2-233

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


× No keyword cloud information.
  41 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients.

Authors:  A B Rickinson; D Crawford; M A Epstein
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

3.  Inhibition of EB virus transformation of non-adherent human lymphocytes by co-cultivation with adult fibroblasts.

Authors:  D J Moss; J H Pope; W Scott
Journal:  Med Microbiol Immunol       Date:  1976-12-01       Impact factor: 3.402

4.  Lymphoid cell line identification and the detection of cross contamination.

Authors:  B R Conner; S Ferrone; M A Pellegrino; R Glaser
Journal:  In Vitro       Date:  1980-05

5.  Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus.

Authors:  Y J Gan; J Chodosh; A Morgan; J W Sixbey
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Induction of Epstein-Barr virus nuclear antigens.

Authors:  D J Moss; T B Sculley; J H Pope
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

7.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

Authors:  M A Epstein; B J Randle; S Finerty; J K Kirkwood
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

Review 8.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

9.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells.

Authors:  A B Rickinson; S Finerty; M A Epstein
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.